391 F. Supp. 3d 485
W.D. Pa.2019Background
- Presque Isle Colon & Rectal Surgery (Plaintiff), an independent physician practice in the Erie MSA, sued Highmark (a dominant Pennsylvania insurer and recent health‑system acquirer) alleging anticompetitive conduct after Highmark cut outpatient reimbursement rates and applied an "All Products" clause in their standard Provider Agreement (PPA).
- Plaintiff alleges Highmark wields monopsony power (buy‑side dominance) — insuring >65% of enrollees in Western Pennsylvania — and uses that leverage to impose predatory rates, excessive audits, steering to Highmark‑owned facilities, and inefficient coding that raise costs for independent physicians.
- Plaintiff originally pleaded Sherman Act §§1 and 2 claims and state common‑law claims; the Court previously dismissed most federal claims with leave to amend. Plaintiff filed an amended complaint repleading §2 claims, recasting its §1 theory as unlawful tying, and adding state/common‑law counts (unjust enrichment, breach of contract/covenant, reformation/rescission).
- Highmark moved to dismiss under Rule 12(b)(6). The court evaluated antitrust standing/antitrust injury, substantive §2 monopsony and attempted monopsony claims, §1 tying theory, Parker state‑action defense, and various pendent/common‑law claims.
- Court holdings (motion partially granted/denied): §2 monopsonization and attempted monopsonization claims proceed; related Pennsylvania antitrust claims survive only to the extent injunctive relief is sought; §1 tying and related state common‑law tying claims dismissed with prejudice; unjust enrichment dismissed with prejudice; breach of contract claim (based on statutory private‑right issues) dismissed but implied covenant claim survives in part; reformation/rescission claim survives.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Antitrust standing/antitrust injury | Highmark's predatory rates plus audits, steering, and coding reduce quantity/quality of independent outpatient services and cause Plaintiff $200k–$300k annual loss. | Allegations are conclusory; no factual showing of reduced competition, consumer harm, or that losses flow from anticompetitive conduct. | Court: At pleading stage plaintiff sufficiently alleged antitrust injury and standing. |
| §2 monopsonization / attempted monopsonization | Highmark has monopsony power (65%+ buy share), willfully maintained/expanded it via predatory rates, audits, steering, and discriminatory treatment to drive independents out. | Reduced rates alone insufficient; allegations are speculative and conclusory as to willfulness and anticompetitive effect. | Court: §2 monopolization and attempted monopsonization claims survive Rule 12(b)(6). |
| §1 tying (buy‑side tying theory) | The All Products Clause ties reimbursement across Highmark products, coercing independent physicians to accept terms and foreclosing competition. | No precedent extends tying liability to a monopsonist; tying doctrine targets seller market power, not buyer coercion. | Court: §1 tying and related state tying claims dismissed with prejudice (no extension of tying doctrine to monopsonist). |
| Parker state‑action defense | DOH approval of the PPA (and All Products Clause) immunizes Highmark under Parker/Midcal. | DOH review was ministerial; no clearly articulated state policy to displace competition and no active supervision of anticompetitive conduct. | Court: Parker immunity rejected—Highmark failed Midcal showing; defendant not entitled to immunity for pleaded conduct. |
| Unjust enrichment | Highmark retained wrongful benefits from reduced reimbursements/clawbacks. | PPA is an express, governing contract; unjust enrichment unavailable where contract governs. | Court: Unjust enrichment dismissed with prejudice. |
| Breach of contract and implied covenant | Highmark breached PPA by discriminatory reimbursement in violation of ACA antidiscrimination provision (incorporated into PPA); alternatively breached covenant by exercising rate discretion in bad faith. | ACA provides no private right of action; plaintiff cannot base breach on a statute it cannot enforce; contract claim fails. | Court: Breach‑of‑contract claim (based on ACA) dismissed; implied covenant/good‑faith claim survives to the extent it alleges bad‑faith exercise of contractual rate‑adjustment discretion. |
| Reformation / rescission | PPA consent was coerced/omitted material terms; equity should reform or rescind. | Equitable remedies require fraud, mistake, or accident and are not a freestanding claim. | Court: Reformation/rescission claim viable at pleading stage—allegations of nondisclosure/coercion suffice to state equitable claim. |
Key Cases Cited
- Kartell v. Blue Shield of Mass., 749 F.2d 922 (1st Cir.) (unilateral price depression by insurers insufficient alone for §2 liability absent special circumstances)
- W. Penn Allegheny Health Sys., Inc. v. UPMC, 627 F.3d 85 (3d Cir.) (antitrust injury and market harm inquiry in healthcare contexts)
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (plausibility standard for pleadings)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (pleading standard and conspiracy requirement)
- LePage's Inc. v. 3M, 324 F.3d 141 (3d Cir.) (assess conduct as whole in antitrust analysis)
- Jefferson Parish Hosp. Dist. No. 2 v. Hyde, 466 U.S. 2 (1984) (tying doctrine focuses on seller market power and coercion)
- Midcal Aluminum, Inc. v. NLRB, 445 U.S. 97 (1980) (two‑part test for Parker state‑action immunity: clear articulation and active supervision)
- Parker v. Brown, 317 U.S. 341 (1943) (state‑action immunity from Sherman Act)
- Weyerhaeuser Co. v. Ross‑Simmons Hardwood Lumber Co., 549 U.S. 312 (2007) (parallels between monopoly and monopsony standards)